Your browser doesn't support javascript.
loading
A rare manifestation of STING-associated vasculopathy with onset in infancy: a case report.
Weidler, Sophia; Koss, Sarah; Wolf, Christine; Lucas, Nadja; Brunner, Jürgen; Lee-Kirsch, Min Ae.
Afiliação
  • Weidler S; Department of Pediatrics, Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. sophia.weidler@uniklinikum-dresden.de.
  • Koss S; Department of Pediatrics, Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • Wolf C; Department of Pediatrics, Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • Lucas N; Department of Pediatrics, Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • Brunner J; Department of Pediatrics, Innsbruck Medical University, Innsbruck, Austria.
  • Lee-Kirsch MA; Faculty of Medicine and Dentistry, Danube Private University, 3500, Krems, Austria.
Pediatr Rheumatol Online J ; 22(1): 9, 2024 Jan 04.
Article em En | MEDLINE | ID: mdl-38178067
ABSTRACT

BACKGROUND:

STING-associated vasculopathy with onset in infancy (SAVI) is a rare type I interferonopathy caused by heterozygous variants in the STING gene. In SAVI, STING variants confer a gain-of-function which causes overactivation of type I interferon (IFN) signaling leading to autoinflammation and various degrees of immunodeficiency and autoimmunity. CASE PRESENTATION We report the case of a 5 year old child and his mother, both of whom presented with systemic inflammatory symptoms yet widely varying organ involvement, disease course and therapeutic response. Genetic testing revealed a heterozygous STING variant, R281Q, in the child and his mother that had previously been associated with SAVI. However, in contrast to previously reported SAVI cases due to the R281Q variant, our patients showed an atypical course of disease with alopecia totalis in the child and a complete lack of lung involvement in the mother.

CONCLUSIONS:

Our findings demonstrate the phenotypic breadth of clinical SAVI manifestations. Given the therapeutic benefit of treatment with JAK inhibitors, early genetic testing for SAVI should be considered in patients with unclear systemic inflammation involving cutaneous, pulmonary, or musculoskeletal symptoms, and signs of immunodeficiency and autoimmunity.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Vasculares / Interferon Tipo I / Síndromes de Imunodeficiência Tipo de estudo: Risk_factors_studies Limite: Child, preschool / Female / Humans / Male Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Vasculares / Interferon Tipo I / Síndromes de Imunodeficiência Tipo de estudo: Risk_factors_studies Limite: Child, preschool / Female / Humans / Male Idioma: En Ano de publicação: 2024 Tipo de documento: Article